EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma

Xiang Liu, Qian Hu, Yuhuan Zheng iD, Wenjiao Tang iD, Ting Niu iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71361 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xiang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Renal Insufficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1.3.5 Project for High Altitude Medicine, Postdoctor Research Fund of West China Hospital, Sichan University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies mainly focused on renal impairment (RI) at multiple myeloma (MM) diagnosis, with few investigating new‐onset RI post‐MM diagnosis. This study aims to indicate the incidence, clinical characteristics and predictive value of new‐onset RI in MM patients.

Methods

We conducted a multicenter, retrospective cohort study including 1953 newly diagnosed MM patients from West China Hospital from July 1, 2008, to February 30, 2024 and the international MMRF‐CoMMpass database. Among them, 1770 patients received novel therapeutic agents including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) as first‐line therapy. RI was defined as serum creatinine higher than 2 mg/dL or impaired creatinine clearance (< 40 mL/min/1.73m 2 ). The association between new‐onset RI and mortality risk was investigated by Kaplan–Meier analysis and Cox proportional hazard models.

Results

Of the cohort, 16.6% developed new‐onset RI, with the majority (67.1%) occurring within 2 years post‐MM diagnosis. The median overall survival (OS) was significantly shorter in new‐onset RI than in those without RI (68 vs. 122 months, p < 0.001). New‐onset RI was an independent risk factor for mortality (HR 1.55, 95% CI 1.28–1.88, p < 0.001), and earlier onset of RI was associated with a higher mortality risk. Moreover, patients with recovery of renal function had prolonged OS compared to those without recovery (95 vs. 64.8 months, p = 0.01). Older age, higher stage of the international stage system (ISS) and RI at diagnosis seemed to be risk factors for new‐onset RI, while first‐line therapy with PIs and IMiDs combinations was associated with a lower risk of RI development (HR 0.69, 95% CI 0.51–0.94, p = 0.017).

Conclusions

In conclusion, the incidence of new‐onset RI is high in MM, and is a significant risk factor for mortality, posing a substantial threat to MM patients. Early identification of high‐risk patients for new‐onset RI and prompt preventive strategies is critical for improving MM prognosis. Trial Registration This study was registered by the Chinese Clinical Trial Registry (ChiCTR2400081476, https://www.chictr.org.cn )

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaRenal InsufficiencyHumansMaleFemaleIncidenceRetrospective StudiesMiddle AgedAgedPrognosisRisk FactorsChinaAdultAged, 80 and over

Stichwörter der Autor:innen

MMRF‐CoMMpass datasetmultiple myelomanew‐onset renal impairmentrisk factor

Autor:innen und Institutionen

  • Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Yuhuan Zheng, Wenjiao Tang, Ting Niu

Förderung

  • 1.3.5 Project for High Altitude Medicine
  • Postdoctor Research Fund of West China Hospital, Sichan University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Liu, X., Hu, Q., Zheng, Y., Tang, W., & Niu, T. (2025). Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma. Cancer Medicine. https://doi.org/10.1002/cam4.71361

Vancouver

Liu X, Hu Q, Zheng Y, Tang W, Niu T. Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma. Cancer Medicine. 2025. doi:10.1002/cam4.71361

BibTeX
@article{Liu2025,
  author = {Liu, Xiang and Hu, Qian and Zheng, Yuhuan and Tang, Wenjiao and Niu, Ting},
  title = {Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71361}
}
Kostenlos starten →